银屑病关节炎患者多重用药与共病负担高:基于理赔数据的年龄和性别分层分析
基于德国BARMER保险数据库2021年11984例接受改善病情抗风湿药治疗的银屑病关节炎患者与性别年龄匹配对照比较,银屑病关节炎患者多重用药(≥5种 concomitant 药物)为49% vs 对照17%,女性52%高于男性45%,且随年龄和共病增加而升高。
要点
- 银屑病关节炎患者多重用药49%,显著高于对照17%。
- 女性多重用药52%,高于男性45%。
- 多重用药随年龄和共病增加而升高。
核心结论
- 银屑病关节炎中多重用药常见,由银屑病关节炎特异性药物和共病常用药物组成,对女性和男性影响相当。
研究设计与样本
- 基于德国BARMER健康保险数据库,纳入2021年接受改善病情抗风湿药治疗的11984例银屑病关节炎患者,与性别和年龄匹配的无炎性关节炎对照比较。
主要发现
- 与对照相比,银屑病关节炎患者所有ATC药物类别均显著更常见,最常见为肌肉骨骼系统药物(81% vs 30%)、免疫调节药物(56% vs 2.6%)、心血管药物(62% vs 48%)、消化道/代谢药物(57% vs 31%)和神经系统药物(50% vs 31%)。
- 银屑病关节炎多重用药为49%,显著高于对照17%;女性为52%,高于男性45%;多重用药随年龄和共病强烈增加。
- RDCI每增加1个单位,年龄校正后的药物数量在男性中增加0.98(95%CI 0.95至1.01)个单位,在女性中增加0.93(95%CI 0.90至0.96)个单位。
- 与对照相比,银屑病关节炎患者药物数量(均值4.9,SD 2.8)在女性中高2.4(95%CI 2.34至2.43)个单位,在男性中高2.3(95%CI 2.21至2.35)个单位。
关键数值与推荐
- 多重用药定义为≥5种 concomitant 药物。
- 共病采用风湿病共病指数(RDCI)和Elixhauser评分评估。
- 药物按解剖治疗化学(ATC)分类组分析。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess polypharmacy in women and men with psoriatic arthritis (PsA). METHODS: From the German BARMER health insurance database, 11 984 persons with PsA and disease-modifying antirheumatic drug therapy in 2021 were included and compared with sex-matched and age-matched controls without inflammatory arthritis. Medications were analysed by Anatomical Therapeutic Chemical (ATC) groups. Polypharmacy (≥5 concomitant drugs) was compared by sex, age and comorbidity using the Rheumatic Disease Comorbidity Index (RDCI) and the Elixhauser Score. The mean difference in the number of medications between persons with PsA and controls was estimated using a linear regression model. RESULTS: Compared with controls, all ATC drug classes were significantly more frequent in persons with PsA, most commonly musculoskeletal (81% vs 30%), immunomodulatory (56% vs 2.6%), cardiovascular (62% vs 48%), alimentary tract/metabolic (57% vs 31%) and nervous system (50% vs 31%) drugs. Polypharmacy was significantly higher in PsA (49%) compared with controls (17%), more frequent in women (52%) compared with men (45%) and strongly increased with age and comorbidity. For each unit increase of the RDCI, the age-adjusted number of medications increased by 0.98 (95% CI 0.95 to 1.01) units in men and 0.93 (95% CI 0.90 to 0.96) units in women. Compared with controls, the number of medications in PsA (mean 4.9 (SD 2.8)) was 2.4 (95%CI 2.34; 2.43) units higher in women and 2.3 (95% CI 2.21 to 2.35) units higher in men. CONCLUSIONS: Polypharmacy is common in PsA and is composed of PsA-specific medication as well as frequent medications for comorbidities, equally affecting women and men.
引用
- Albrecht K, Regierer AC, Strangfeld A, et al. High burden of polypharmacy and comorbidity in persons with psoriatic arthritis: an analysis of claims data, stratified by age and sex. RMD Open. 2023. PMID: 36894195. doi:10.1136/rmdopen-2022-002960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。